PUBLISHER: Grand View Research | PRODUCT CODE: 1771609
PUBLISHER: Grand View Research | PRODUCT CODE: 1771609
UK Alzheimer's Therapeutics Market Size, Share & Trends Analysis Report By Product (Cholinesterase Inhibitors, NMDA Receptor Antagonist Combination Drug), By End Use (Hospital Pharmacy, Retail Pharmacy), And Segment Forecasts, 2025 - 2033
UK Alzheimer's Therapeutics Market Trends:
The UK Alzheimer's therapeutics market size was estimated at USD 263.66 million in 2024 and is projected to reach USD 498.80 million by 2033, growing at a CAGR of 7.84% from 2025 to 2033. The increasing prevalence of Alzheimer's disease in the UK is driving demand for effective and innovative treatment solutions. The growing proportion of elderly individuals is leading to a surge in cognitive health issues, resulting in more frequent diagnoses. The expanding over-65 population is directly linked to a rising number of Alzheimer's cases, necessitating expanded access to advanced therapeutics. The trend toward early screening and better public awareness allows healthcare systems to identify the condition at earlier stages.
Drug development and clinical research innovations support market growth across the forecast period. Pharmaceutical companies are focusing on targeted therapies, including monoclonal antibodies and disease-modifying treatments, which are demonstrating potential in clinical trials. Strong engagement in research collaborations with academic institutions is accelerating the pace of therapeutic innovation. For instance, in August 2024, Eisai Co., Ltd. and Biogen Inc. announced that Leqembi received Marketing Authorization from the Medicines and Healthcare products Regulatory Agency (MHRA) for use in Great Britain. The UK's established clinical trial environment attracts international drug developers to test novel Alzheimer's treatments. Advanced imaging techniques and biomarker research aid in early detection and effective treatment monitoring. These advancements facilitate the development of precision therapies tailored to disease stages and individual responses. As a result, the treatment landscape is gradually shifting toward more personalized and outcome-driven approaches.
Private sector investments and strategic partnerships are further strengthening the market outlook. Key players are expanding their product pipelines and engaging in licensing deals to enhance their competitiveness. Pharmaceutical companies are launching new products and reformulating existing drugs to extend their clinical benefits. In May 2024, Takeda and AC Immune SA entered into an exclusive global option and license agreement focused on AC Immune's active immunotherapy programs targeting toxic amyloid beta (AB) species. The deal includes ACI-24.060, a vaccine candidate designed for the treatment of Alzheimer's disease.
UK Alzheimer's Therapeutics Market Report Segmentation
This report forecasts revenue growth at a country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the UK Alzheimer's therapeutics market report based on product and end use:
- Product Outlook (Revenue, USD Million, 2021 - 2033)
- Cholinesterase Inhibitors
- Donepezil
- Galantamine
- Rivastigmine
- NMDA Receptor Antagonist
- Combination Drug
- Monoclonal Antibodies
- Pipeline Drugs
- End Use Outlook (Revenue, USD Million, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- E-commerce
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Product
- 1.2.2. End Use
- 1.3. Estimates and Forecast Timeline
- 1.4. Research Methodology
- 1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
- 1.6. Information Analysis
- 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Data Visualization
- 1.8. Model Details
- 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. UK Alzheimer's Therapeutics Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
- 3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
- 3.3.1.1. Supplier Power
- 3.3.1.2. Buyer Power
- 3.3.1.3. Substitution Threat
- 3.3.1.4. Threat of New Entrants
- 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
- 3.3.3. Pipeline Analysis
- 3.3.4. Patent Expiry Analysis
- 3.3.5. Pricing Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
Chapter 4. UK Alzheimer's Therapeutics Market: Product Business Analysis
- 4.1. Product Market Share, 2024 & 2033
- 4.2. Product Segment Dashboard
- 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (USD Million)
- 4.4. Cholinesterase Inhibitors
- 4.4.1. Cholinesterase Inhibitors Market, 2021 - 2033 (USD Million)
- 4.4.2. Donepezil
- 4.4.2.1. Donepezil Market, 2021 - 2033 (USD Million)
- 4.4.3. Galantamine
- 4.4.3.1. Galantamine Market, 2021 - 2033 (USD Million)
- 4.4.4. Rivastigmine
- 4.4.4.1. Rivastigmine Market, 2021 - 2033 (USD Million)
- 4.5. NMDA Receptor Antagonist Combination Drug
- 4.5.1. NMDA Receptor Antagonist Combination Drug Market, 2021 - 2033 (USD Million)
- 4.6. Combination Drug
- 4.6.1. Combination Drug Market, 2021 - 2033 (USD Million)
- 4.7. Monoclonal Antibodies
- 4.7.1. Monoclonal Antibodies Market, 2021 - 2033 (USD Million)
- 4.8. Pipeline Drugs
- 4.8.1. Pipeline Drugs Market, 2021 - 2033 (USD Million)
Chapter 5. UK Alzheimer's Therapeutics Market: End Use Business Analysis
- 5.1. End Use Market Share, 2024 & 2033
- 5.2. End Use Segment Dashboard
- 5.3. Market Size & Forecasts and Trend Analysis, by End Use, 2021 to 2033 (USD Million)
- 5.4. Hospital Pharmacies
- 5.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
- 5.5. Retail Pharmacies
- 5.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
- 5.6. E-commerce
- 5.6.1. E-commerce Market, 2021 - 2033 (USD Million)
Chapter 6. Competitive Landscape
- 6.1. Participant Overview
- 6.2. Company Market Position Analysis
- 6.3. Company Categorization
- 6.4. Strategy Mapping
- 6.5. Company Profiles/Listing
- 6.5.1. Eisai Co., Ltd
- 6.5.1.1. Overview
- 6.5.1.2. Financial Performance
- 6.5.1.3. Product Benchmarking
- 6.5.1.4. Strategic Initiatives
- 6.5.2. Novartis AG
- 6.5.2.1. Overview
- 6.5.2.2. Financial Performance
- 6.5.2.3. Product Benchmarking
- 6.5.2.4. Strategic Initiatives
- 6.5.3. AbbVie Inc
- 6.5.3.1. Overview
- 6.5.3.2. Financial Performance
- 6.5.3.3. Product Benchmarking
- 6.5.3.4. Strategic Initiatives
- 6.5.4. Supernus Pharmaceuticals, Inc.
- 6.5.4.1. Overview
- 6.5.4.2. Financial Performance
- 6.5.4.3. Product Benchmarking
- 6.5.4.4. Strategic Initiatives
- 6.5.5. H. Lundbeck A/S
- 6.5.5.1. Overview
- 6.5.5.2. Financial Performance
- 6.5.5.3. Product Benchmarking
- 6.5.5.4. Strategic Initiatives
- 6.5.6. Biogen
- 6.5.6.1. Overview
- 6.5.6.2. Financial Performance
- 6.5.6.3. Product Benchmarking
- 6.5.6.4. Strategic Initiatives
- 6.5.7. AC IMMUNE SA
- 6.5.7.1. Overview
- 6.5.7.2. Financial Performance
- 6.5.7.3. Product Benchmarking
- 6.5.7.4. Strategic Initiatives
- 6.5.8. F. Hoffmann-La Roche Ltd
- 6.5.8.1. Overview
- 6.5.8.2. Financial Performance
- 6.5.8.3. Product Benchmarking
- 6.5.8.4. Strategic Initiatives
- 6.5.9. Daiichi Sankyo Company, Limited
- 6.5.9.1. Overview
- 6.5.9.2. Financial Performance
- 6.5.9.3. Product Benchmarking
- 6.5.9.4. Strategic Initiatives
- 6.5.10. Johnson & Johnson Services, Inc.
- 6.5.10.1. Overview
- 6.5.10.2. Financial Performance
- 6.5.10.3. Product Benchmarking
- 6.5.10.4. Strategic Initiatives
- 6.5.11. TauRx Pharmaceuticals Ltd.
- 6.5.11.1. Overview
- 6.5.11.2. Financial Performance
- 6.5.11.3. Product Benchmarking
- 6.5.11.4. Strategic Initiatives
- 6.5.12. Eli Lilly and Company
- 6.5.12.1. Overview
- 6.5.12.2. Financial Performance
- 6.5.12.3. Product Benchmarking
- 6.5.12.4. Strategic Initiatives
- 6.5.13. Alzheon
- 6.5.13.1. Overview
- 6.5.13.2. Financial Performance
- 6.5.13.3. Product Benchmarking
- 6.5.13.4. Strategic Initiatives
- 6.5.1. Eisai Co., Ltd
List of Tables
- Table 1 List of secondary sources
- Table 2 List of abbreviations
- Table 3 UK alzheimer's therapeutics market, by product, 2021 - 2033 (USD Million)
- Table 4 UK alzheimer's therapeutics market, by end use, 2021 - 2033 (USD Million)
List of Figures
- Fig. 1 UK alzheimer's therapeutics market segmentation
- Fig. 2 Market research process
- Fig. 3 Data triangulation techniques
- Fig. 4 Primary research pattern
- Fig. 5 Market research approaches
- Fig. 6 Value-chain-based sizing & forecasting
- Fig. 7 Market formulation & validation
- Fig. 8 Market snapshot
- Fig. 9 Therapeutic approach and application outlook (USD Million)
- Fig. 10 Competitive landscape
- Fig. 11 UK alzheimer's therapeutics market dynamics
- Fig. 12 UK alzheimer's therapeutics market: Porter's five forces analysis
- Fig. 13 UK alzheimer's therapeutics market: PESTLE analysis
- Fig. 14 Product market, 2021 - 2033 (USD Million)
- Fig. 15 Cholinesterase inhibitors market, 2021 - 2033 (USD Million)
- Fig. 16 Donepezil market, 2021 - 2033 (USD Million)
- Fig. 17 Galantamine market, 2021 - 2033 (USD Million)
- Fig. 18 Rivastigmine market, 2021 - 2033 (USD Million)
- Fig. 19 NMDA receptor antagonist combination drug market, 2021 - 2033 (USD Million)
- Fig. 20 Combination drug market, 2021 - 2033 (USD Million)
- Fig. 21 Monoclonal antibodies market, 2021 - 2033 (USD Million)
- Fig. 22 Pipeline drugs market, 2021 - 2033 (USD Million)
- Fig. 23 End use market, 2021 - 2033 (USD Million)
- Fig. 24 Hospital pharmacies market, 2021 - 2033 (USD Million)
- Fig. 25 Retail pharmacies market, 2021 - 2033 (USD Million)
- Fig. 26 E-commerce market, 2021 - 2033 (USD Million)
- Fig. 27 Company categorization
- Fig. 28 Company market position analysis
- Fig. 29 Strategic framework
